Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opportunity in PTBE expected to exceed USD 1 billion | Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog

Curatis Holding AG / Key word(s): Change in Forecast/Strategic Company Decision Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opportunity in PTBE expected to exceed USD 1 billion | Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog 23-May-2025 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR

Liestal, Switzerland, 23 May 2025: An epidemiological market study commissioned by Curatis Holding AG (SIX:CURN, “Curatis”) shows that the target patient group is substantially larger than previous estimates. In the US alone, over 150,000 patients suffer from peritumoral brain edema (PTBE) in association with milagnant tumors. In previous clinical studies, human corticorelin (C-PTBE-01), demonstrated significant benefits in the treatment of PTBE. “The prospect of developing a potential blockbuster drug with that can contribute significantly to the quality of life of many patients, combined with the potential of maintaining the efficacy of immunotherapies for these patients, is very motivating and exciting.”, said Dr. Roland Rutschmann, Curatis CEO.

Key statements

• Corticorelin (hCRH), a 41 amino acid endogenous polypeptide, has demonstrated the ability to positively impact the blood-brain barrier after a disruption due to the underlying malignant tumor.
• Curatis intends to develop corticorelin to treat PTBE in primary and metastatic brain tumors.
• The medical need for new treatments is increasingly high, as conventional treatment with corticosteroids often leads to serious glucocorticoid-induced side effects. Additionally, corticosteroids can interfere with certain chemotherapies and modern immunotherapies, which are rapidly growing in importance.
• Curatis is strengthening the team with Kirsty Crame, MD, as Chief Medical Officer and Timm Trenktrog, PhD, as Head of Chemistry, Manufacturing and Controls (CMC).
• The application for the meeting with the FDA will be filed in Q2 2025.

Target patient group significantly larger than previous estimates